Anti-Epidermal Growth Factor Receptor (EGFR) Aptamer Synthesis and Modification Service
Cell surface proteins circulate to some extent within cells, and many surface receptors can be actively internalized in response to ligand binding. Aptamers that bind to cell surface receptors have been used to study the delivery of various drugs to tumor cells.
CD Bioparticles offers an anti-EGFR aptamer synthesis and modification service through which we synthesize and modify aptamers that can, in principle, be used to deliver drugs or other cytotoxic substances to cancer cells expressing EGFR. This will enable fundamental research into the role of aptamers in cancer drug delivery.
Anti-Epidermal Aptamer Service Background
EGFR (Epidermal Growth Factor Receptor) is a receptor for an epithelial growth factor (EGF) involved in cell proliferation and signaling and is a transmembrane receptor tyrosine kinase. The binding of EGFR to its cognate ligands leads to receptor dimerisation, resulting in autophosphorylation, receptor internalisation and activation of intracellular signaling pathways. Overexpression of EGFR is associated with a wide range of cancers, with EGFR being overexpressed in many solid tumours such as epidermoid carcinoma, malignant glioma, and lung, pancreatic and breast cancer, making it one of the most sensitive therapeutic targets. It is also an ideal target for aptamer-mediated delivery of cytotoxic drugs to cancer cells.
It has been shown that anti-EGFR aptamers can be coupled to gold nanoparticles by a simple hybridization method and can be quantitatively delivered to EGFR-expressing cells via receptor-mediated endocytosis to provide targeted drug delivery therapy.
Fig. 1 Epidermal growth factor receptor pathway as a therapeutic target for metastatic colorectal cancer. (Ciftci R, et al., 2016)
Our Anti-EGFR Aptamer Services
CD Bioparticles offers anti-EGFR aptamer synthesis and modification services. We have many years of experience in custom aptamer design and modification and can provide aptamer customization services for high-affinity target proteins suitable for your application. Our services include but are not limited to the following:
We will work with you to design aptamers specifically for the EGFR receptor or any other target protein of interest.
-
Anti-EGFR Aptamer Synthesis
We offer customized anti-EGFR aptamer synthesis services using a range of techniques including solid-phase synthesis, enzymatic synthesis, and chemical synthesis.
-
Anti-EGFR Aptamer Modification
We can further modify anti-EGFR aptamer to improve their binding affinity, stability, and specificity to the target protein. This includes chemical modifications, conjugation to different tags or fluorophores, and incorporation of anti-nuclease ligands.
-
Characterization of Anti-EGFR Aptamers
A range of assays can be used to characterize the binding properties of anti-EGFR aptamer, including surface plasmon resonance (SPR), fluorescence polarisation (FP), and gel shift assays.
-
Anti-EGFR Aptamers Targeted Drug Delivery
We can demonstrate that the aptamers we develop can direct tissue-specific drug uptake through in vitro and in vivo assays.
-
Anti-EGFR Aptamer Optimization
We offer optimization services to improve the properties of aptamers for your specific application. This includes optimization of the aptamer sequence, modification of the aptamer structure, and optimization of the attachment chemistry.
Contact Us
CD Bioparticles offers services to synthesize and modify aptamers for targeted drug delivery. Our team has developed a variety of aptamers that bind to cell surface receptors. Please contact us if you are interested in our services.
Quotations and Ordering
References
-
Wang, DL.; et al. Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity. Biochem Biophys Res Commun. 2014; 453 (4): 681-5.
-
Ciftci, R.; Tural, D. Anti-Epidermal Growth Factor Receptor (EGFR) Treatment in Patients with Metastatic Colorectal Cancer. 2016.
